By: Dr. Nikhil Wagle
Leader of The MBCProject, Komen-Funded Researcher
We recently caught up with Dr. Nikhil Wagle, leader of The Metastatic Breast Cancer (MBC) Project and Komen-funded researcher. In the Q&A below, Dr. Wagle answers questions about his personal motivation, applying for grants as a young investigator, and how he and his colleagues worked with patients to develop the groundbreaking MBC Project.What motivated you to pursue a career in breast cancer research?
I have been drawn to medicine and science for as long as I can remember. Once I started medical school, I became really interested in cancer research – largely because there was so much we didn’t know, yet it affects so many. We were (and still are) in desperate need of more treatments. Throughout my training as a medical oncologist, I saw many women and men with both early-stage and metastatic breast cancer. In some cases, we really understood the biology of a patient’s tumor and what was driving it. We could give those patients drugs to target the tumor, and those patients would do really well. Those were great moments. But so many times that was not the case. We didn’t know the biology, or didn’t have a marker or test to advise us as to which drug we should use. That’s what led me to pursuing a career in trying to understand precision medicine.
You were a recipient of a Komen Career Catalyst Research Grant – our grant mechanism aimed at helping young investigators start independent research careers. Tell me what it’s like to get funding as an early-career investigator.
One of the issues with a career in research is that even if you’re passionate and want to make a difference, it is challenging to realize that goal because you have to find funding. This is particularly difficult as a young researcher. I was very fortunate to have received a Career Catalyst Research Award from Komen at a key point early in my independent research career. That grant provided me with funding to pursue laboratory studies of treatment resistance in patients with ER+ metastatic disease. This ongoing project in my lab is now starting to yield important insights about how treatment resistance occurs and how we might overcome that resistance. This funding was critical in helping me launch this investigation just as I was starting out.
We at Komen were delighted to announce our support for the innovative Metastatic Breast Cancer (MBC) Project. How did the MBC Project come about?
There are some clear emerging patterns in cancer research. First, studying tumor samples from patients is essential. Tumor samples enable us to make really important discoveries and advances more quickly. Many of the major discoveries and novel treatments that have come out over the last five to 10 years have relied on these samples. Second, many academic cancer centers doing breast cancer research are only able to collect tissue from patients who are cared for at that institution, which accounts for only a small fraction of patients with breast cancer in the country.
By some estimates 85 percent of patients with cancer in the U.S. are cared for in community settings – not large academic cancer centers. That means the vast majority of cancer patients in the U.S. have never been asked if they would be willing to share their tumor samples and medical information for biomedical research.
We thought that if asked, patients would be very willing to participate in these studies. That’s what spawned this idea. In the era of social media, the internet, advocacy groups, and patient empowerment, we hypothesized that if we built something that would allow any patient to participate – regardless of where they live – together we could accelerate research and discover more about the biology of metastatic breast cancer, and even identify potential treatment strategies. So, last October we launched the Metastatic Breast Cancer Project and our website.
Dr. Nikhil Wagle"We knew from the beginning that this would be a different type of study, and felt really strongly that patients should have a voice in how this project should be developed. Our view was, if we were going to do a project that was all about the patient-researcher partnership, it should be true from day one."
Dr. Nikhil Wagle
"We knew from the beginning that this would be a different type of study, and felt really strongly that patients should have a voice in how this project should be developed. Our view was, if we were going to do a project that was all about the patient-researcher partnership, it should be true from day one."
How were patients involved in this project?
We knew from the beginning that this would be a different type of study, and felt really strongly that patients should have a voice in how this project should be developed. Our view was, if we were going to do a project that was all about the patient-researcher partnership, it should be true from day one.
During the San Antonio Breast Cancer Symposium in 2014, we met with as many MBC patients and advocates as we could find. We didn’t even have a name for our idea – just wanted to put it out there and gauge interest. Would they be interested in participating? Would they tell others?
We learned a lot from those discussions. First and foremost, patients and advocates supported the idea. But second, there were some concerns. They wanted to make sure what we were doing wasn’t redundant with other projects (which would just be a waste of energy and money). It was also important to the patients that, should we move forward, our work and learnings would not just benefit us, but the whole research community. So right there, at the conception of the project, we made a commitment that all data we collected would be publicly available for any researcher who could use it.
Those are just a couple of ways in which the patient perspective influenced us in the beginning, and continues to influence us today. Conversations with patients and advocates also helped guide the site design, messaging, images, and our overall process.
It’s amazing to have the patient voice integrated into everything we do every single day. We’re thrilled to have created a two-way dialogue between all of our patient participants and the researchers, regularly updating patients on where the project has been going, providing status updates, and what we’re learning. Many of our patients have told us how other studies they’ve participated in don’t provide any updates. They may not even be informed when a study they participate in has ended. So we do our best to make sure that our participants are always informed of the impact they’re making.
You mentioned that you share things you’re learning with the participants. Any learnings you can share with us? More than 2,900 women and men with breast cancer from the U.S., Canada and other countries have signed up to participate in the study, almost all of whom also opted to share information about their diagnosis, treatment, and experiences with cancer… This has allowed us to learn a great deal about MBC right from the start – before even going into the laboratory. For example, we were able to identify a group of patients who all had one thing in common – an extraordinary response to a specific treatment (for example, platinum chemotherapy). Knowing that these individuals share this unique quality raises the question, “Why?” Since we are obtaining saliva and tissue samples from patients, we can now analyze their individual samples to see if we can understand why this group of patients had a particularly good response to that chemotherapy. If we can answer this question, then maybe we can understand something that will apply to more people.
What’s the biggest challenge you’ve had to overcome in your career?
There are so many questions we want to answer! Not only that, there’s a strong sense of urgency to answer them, because people’s lives are at stake today. The challenge is that the research process tends to go more slowly than you hope. There are barriers – logistical, funding, data sharing – that can make research slower or less-effective. We are constantly trying to overcome these barriers and make research happen more smoothly. It’s part of what inspired this project. At least in some ways, this can help break down the issues of silos, and create a pool of knowledge to advance our understanding of metastatic disease.
What’s one thing you think many patients may not know about breast cancer research but you’d like them to know?
Significant progress is being made. I know there are questions about whether we are making progress, whether advances are happening – I hear it from patients often. From my vantage point, we HAVE made progress, and are now at an incredibly promising time in research – both with the kinds of technology available and new therapies on the horizon. I’m hopeful that we are going to make really significant advances in the treatment of cancer, and soon.
You are clearly very passionate about this research, and extremely busy working to make an impact in the lives of patients today. When do you sleep?
Life is busy and there’s a lot to do, but there are so many people who are dedicated and passionate about making a difference. It’s not just me (or any one individual)! There are countless individuals involved. The MBC Project is a multidisciplinary effort with my team collaborating with several other research teams, not to mention all of our incredible advocacy partners and patients. It’s a team effort to the extreme.
Return to Blog Home
Metastatic Breast Cancer Update
By: Paula Schneider
We need to better understand: why breast cancer spreads; why some patients are impacted (sometimes years after their initial breast cancer diagnosis) ...
Komen Grantee Dr. Chad Pecot: Clinician-Scientist, Husband, Father & Cancer Survivor
By: Jamie Stanford, Ph.D.
Dr. Chad Pecot holds many titles: oncologist, Komen-funded clinician-scientist, husband, father and cancer survivor....
Gaining New Ground in Research
Headlines & Helpful Information
By: Dr. George Sledge and Dr. Jennifer Pietenpol
Breakthroughs in breast cancer research happen every single day – just ask the researchers, postdoctoral fellows and physicians working long hours and...
Q&A with Dennis Slamon, M.D., Ph.D., Winner of the 2017 Brinker Award for Scientific Distinction in Clinical Research
By: Dr. Dennis Slamon
When we saw that the drug trastuzumab (Herceptin) really was safe and was effective, and we were seeing patients respond dramatically to the drug when...
Q&A with Alan Ashworth, Ph.D., F.R.S., Winner of the 2017 Brinker Award for Scientific Distinction in Basic Science
By: Dr. Alan Ashworth
It was an interesting scientific opportunity – to be involved in discovering the BRCA2 gene. And once I got involved in that, I became very interested...
Komen Clinical Trial Shows Promise in Treating HER2-Positive Breast Cancer
By: David Vaught, Ph.D.
Recently, work by one of our Komen-funded investigators made its way from the lab to a clinical trial, revealing new information about the treatment o...
Making Metastatic Breast Cancer Research a Priority
By: Stephanie Birkey Reffey
Research is just one way Susan G. Komen® and other organizations are working to improve outcomes for those living with metastatic breast cancer (MBC),...
Big Possibilities with Big Data in Breast Cancer
By: Stephanie Birkey Reffey, Ph.D.
The potential for Big Data in breast cancer is virtually endless – literally the world at your fingertips. Imagine what could happen to the pace of r...
Stories of Impact for 2016
By: Susan G. Komen
In 2016, Susan G. Komen announced its Bold Goal, to reduce the current number of breast cancer deaths by 50 percent in the U.S. by 2026. In support of...
Q&A with Monica Morrow, M.D., FACS, Winner of the 2016 Brinker Award for Scientific Distinction in Clinical Research
By: Dr. Monica Morrow
We recently spoke with Dr. Monica Morrow, winner of the 2016 Brinker Award for Scientific Distinction in Clinical Research, about her career in breast...
Q&A with Charles Perou, Ph.D., Winner of the 2016 Brinker Award for Scientific Distinction in Basic Science
By: Dr. Charles Perou
We recently spoke with Dr. Charles Perou, winner of the 2016 Brinker Award for Scientific Distinction in Basic Science, about his career in breast can...
Inflammatory Breast Cancer… What’s That?
By: Ginny Mason, RN
When the surgeon sat down across from me and took my hand, I should have known it wasn't good. He said, "You have inflammatory breast cancer. On a sca...
A Clarion Call: Changing the Reality of Metastatic Breast Cancer
By: Dr. Judy Salerno and Dr. Danny Welch
Today’s Metastatic Breast Cancer Awareness Day underscores a disturbing reality in breast cancer. Despite all the progress that has been made over thr...
Spotlight on Science: Genetics and Side Effects - Dr. Bryan Schneider
By: Susan G. Komen
One of the most promising new trends in cancer science is the search for personalized medicines – finding treatments that are right for individual pat...
Taking on Triple Negative Breast Cancer
The thought that it might be breast cancer never crossed Kathy’s mind when she felt an excruciating pain in her chest last November. After working as ...
The Cancer Moonshot: Ready, Willing and Able
By: Dr. Judy Salerno
President Obama’s announcement of a cancer “Moonshot” - with Vice President Joe Biden at the controls - is sending positive shockwaves through the can...
Q&A with Martine J. Piccart, M.D., Ph.D., Winner of the 2015 Brinker Award for Scientific Distinction in Clinical Research
In the quest for personalized medicine, scientists have been studying why some breast cancers respond to certain therapies and others don’t. Dr. Marti...
Q&A with Myles Brown, M.D., Winner of the 2015 Brinker Award for Scientific Distinction in Basic Science
In the quest for better patient outcomes, scientists have been studying why some breast cancers stop responding to therapies and develop resistance. ...
Komen Breast Care Helpline Advice: Using Knowledge To Empower
Diagnostic mammograms, breast ultrasounds, needle biopsies – these are just a few tests a woman may have if there is any question whether she has bre...
Hospitals, Researchers and Advocates Come Together to Push Progress in Clinical Trials
By: Kari Wojtanik
Treatment of breast cancer has greatly improved due to lessons learned through clinical trials. Thanks to researchers and the bold women and men who a...
The ‘Omics’ and the Future of Cancer Research
In 2014 Congress declared May as National Cancer Research Month to recognize innovative work being done to find cures for cancer in all its forms....
An Exciting Scientific Discovery – the RECQL Breast Cancer Susceptibility Gene
By: Judy Salerno, President & CEO
One of the most important elements of the Susan G. Komen mission is funding breast cancer research, and today, we’re excited to share an important bre...
Komen Funding Launches One Investigator’s Career as He Works to Prevent Breast Cancer Metastasis to the Brain
Susan G. Komen has funded over $135 million in research grants for young investigators. These research dollars are vital as funding for scientific res...
Your Genes, Environment and Breast Cancer Risk: the Two Sister Study
Why do some women develop breast cancer and not others? And why do some women develop breast cancer at a much younger age? We know that factors like...
Breast Cancer Metastasis: Are We Making Progress?
Metastatic disease (breast cancer that has spread beyond the breast to other organs in the body) is what kills cancer survivors – like my two friends ...
Traveling More Than 5,500 Miles to Fight Breast Cancer Disparities
I am honored to celebrate Black History Month by sharing what I have learned over my career as a surgical oncologist studying the many factors that co...
2014 Brinker Award: Joan S. Brugge
By: Joan S. Brugge
I am highly honored to be the recipient of this year’s Brinker Award. I share this honor with the extremely talented young investigators in my labora...
2014 Brinker Award: Mitch Dowsett
By: Mitch Dowsett
As a teenager, I was fascinated by the genetic code, and I still find it astonishing that the immense complexity of living things is derived through a...
Progress Towards a Cure for Breast Cancer: Small Steps and Big Leaps
By: Dr. George Sledge, Jr., MD.
As a physician and cancer researcher I am often asked, “when will we find a cure for breast cancer?” The answer is complicated, in part because of wha...
MBC Patients Need More
By: Jacqueline McKnight
Metastatic breast cancer (MBC), or Stage IV breast cancer, is different from early-stage breast cancers because it cannot be cured.People living with ...
Does local therapy choice improve survival?
By: Ann H. Partridge, M.D., M.P.H.
Over the past decade, there has been a substantial increase in the number of women with early breast cancer who are choosing to undergo prophylactic c...
New Possibilities for HER2-Positive Breast Cancer
By: Glendon Zinser, Ph.D.
Dr. Prat’s research focuses on HER2-positive breast cancer, which is a very aggressive type of cancer and it accounts for 15-20 percent of all diagnos...
Understanding Metastatic Breast Cancer & Research
By: Cheryl Jernigan, CPA, FACHE
Komen Kansas City’s June 18th webinar offered both sobering and hopeful information, which was all too real for many of us. Monday morning, we lost a ...
Advancing Survivorship through Multilevel Collaborations
Since 1982, Komen has played a critical role in many advances in the fight against breast cancer – transforming how the world talks about and treats t...
Reducing Surgeries and Putting Patients First
After serving as a public policy advocate and volunteer for Susan G. Komen for many years, I decided to focus my interest in research advocacy and joi...
Clinical Trial Impact becomes Personal for Advocate in Science Member
By: Karen Durham
After finding a suspicious lump in October 2008 and undergoing a series of tests and scans my diagnosis was confirmed in Feburary 2009 – I had metasta...
We Have Heard YOU! The Collateral Damage Project
By: Dr. Susan Love
The Dr. Susan Love Research Foundation launched the Collateral Damage from Breast Cancer Treatment project in October to kick off Breast Cancer Awaren...
Voices of Impact – Dr. Gordon B. Mills
Dr. Gordon B. Mills received the 2013 Brinker Award for Scientific Distinction in Basic Science for his significant contributions to breast cancer res...
Voices of Impact – Dr. Edith A. Perez
Early in my life, I wanted to be part of something that was innovative, unique and great, but I didn’t know exactly what that would be. When I started...
A One of a Kind Donation
By: Julie Guevara
Susan G. Komen Orange County recently embarked on an exciting partnership with MemorialCare Medical Group and the Susan G. Komen Tissue Bank at the In...
Clinical Trials: A Way for You to Help Advance Breast Cancer Care
By: Elly Cohen
After being diagnosed with early-stage breast cancer in 1998, I had the option of having either a lumpectomy, followed by radiation, or a mastectomy. ...
Voices of Impact – Dr. Anna Wu / Dr. Iona Cheng
We’ve known each other for about 10 years; we first met at USC and more recently because of a collaborative Breast Cancer Survivorship Study in Califo...
Voices of Impact – Dr. Dan Welch
When I was young I thought I wanted to be a physician. As one of my pre-med requirements at UC Irvine, I worked in Garth Nicolson’s lab on cancer and ...
Voices of Impact – Dr. Judy Salerno / Health of Women [HOW] Study
Hello and thanks to all of you for such a warm welcome as I assume my new role as President and CEO of Susan G. Komen. I’ll be posting on our blog fre...
Encouraging the Immune System to Fight Cancer
By: Krissa Smith, Scientific Grants Manager and Nora Disis, Professor
In the fight against breast cancer, a patient’s immune system plays an important role. The immune system can detect and destroy foreign substances or ...
Voices of Impact – Dr. Neil Spector
For me, becoming a doctor was a natural fit between science and the ability to transform it into something clinically meaningful. I chose oncology as ...
A Huge Challenge Ahead
By: Anna Cabanes
Two years ago, after the release of a report that concluded that there is a lack of robust data linking environmental exposures and the risk of breast...
Voices of Impact – Dr. Tom Marshall
It was innate scientific curiosity that led me to a career in breast cancer research, but it’s the women I’ve met throughout my time as a Komen Fellow...
Komen Research Grantees Lead the Way to Understanding Familial Breast Cancer
By: Margaret Flowers
Breast cancer occurs when there is an accumulation of defects or mutations in genes that control the growth and division of cells or genes that are im...